Rhumbline Advisers Morphic Holding, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$26.12 - $34.07 $357,243 - $465,975	13,677 Added 26.45%	65,379 $2.23 Million
Q1 2024 May 09, 2024	BUY	$26.64 - $40.31 $48,751 - $73,767	1,830 Added 3.67%	51,702 $1.82 Million
Q4 2023 Feb 08, 2024	BUY	$19.95 - $31.0 $16,538 - $25,699	829 Added 1.69%	49,872 $1.44 Million
Q3 2023 Nov 09, 2023	BUY	$21.33 - $59.42 $141,481 - $394,132	6,633 Added 15.64%	49,043 $1.12 Million
Q2 2023 Aug 08, 2023	BUY	$34.33 - $62.11 $229,873 - $415,888	6,696 Added 18.75%	42,410 $2.43 Million
Q1 2023 May 11, 2023	BUY	$26.01 - $48.69 $39,535 - $74,008	1,520 Added 4.45%	35,714 $1.34 Million
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $14,049 - $17,675	582 Added 1.73%	34,194 $915,000
Q3 2022 Nov 10, 2022	BUY	$22.23 - $33.37 $59,376 - $89,131	2,671 Added 8.63%	33,612 $951,000
Q2 2022 Aug 11, 2022	BUY	$19.74 - $43.01 $179,278 - $390,616	9,082 Added 41.55%	30,941 $671,000
Q1 2022 May 12, 2022	BUY	$36.25 - $52.02 $38,388 - $55,089	1,059 Added 5.09%	21,859 $878,000
Q4 2021 Feb 10, 2022	BUY	$43.27 - $65.72 $20,769 - $31,545	480 Added 2.36%	20,800 $986,000
Q3 2021 Nov 12, 2021	BUY	$53.61 - $67.5 $44,710 - $56,295	834 Added 4.28%	20,320 $1.15 Million
Q2 2021 Aug 05, 2021	BUY	$45.13 - $64.99 $283,326 - $408,007	6,278 Added 47.53%	19,486 $1.12 Million
Q1 2021 May 06, 2021	SELL	$29.77 - $84.85 $24,262 - $69,152	-815 Reduced 5.81%	13,208 $836,000
Q4 2020 Feb 10, 2021	BUY	$25.66 - $34.55 $26,173 - $35,241	1,020 Added 7.84%	14,023 $470,000
Q3 2020 Nov 12, 2020	SELL	$22.51 - $30.11 $45,650 - $61,063	-2,028 Reduced 13.49%	13,003 $356,000
Q2 2020 Aug 13, 2020	BUY	$12.65 - $29.57 $190,142 - $444,466	15,031 New	15,031 $407,000

Others Institutions Holding MORF

# of Institutions

Shares Held

4.7M

Call Options Held

Put Options Held

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account